CVS soars as fourth-quarter earnings exceed every Wall Street estimate
Shares of CVS Health are soaring in the premarket after the drugstore and insurance company delivered fourth-quarter earnings per share that surpassed every analyst’s estimate — the company’s EPS of $1.19 crushed the consensus estimate of $0.92 — and reported better-than-expected revenues to boot.
A bigger surprise on the bottom line than the top line usually means one thing: effective expense control.
The medical benefit ratio (that is, the share of premiums collected spent on medical care) in its insurance ratio was 94.8%, lower than projected. That’s a positive, since it means more money is left over for the company to claim as profits.
Its peer, Cigna, reported larger-than-expected outlays to cover patients’ costs when it released earnings in late January, sending shares sharply lower.
Management’s guidance for 2025, however, was a little on the low side. Adjusted earnings per share are projected to come in between $5.75 and $6.00, while the consensus estimate currently sits at the top of that range. Projected sales of “at least $385.9 billion” are a bit shy of where the sell side is at, too.